A set of ~800 largely isogenic deficiency stocks created by FLP-induced recombination between FRT-carrying transgenic insertions; molecularly defined deletion endpoints correspond to initial location of the progenitor insertions. Designed to fill gaps in deletion coverage and breakpoint placement; also used to replace older available deficiencies that have not been molecularly mapped.
Dp(1;3)DC130 covers the Df(1)BSC823 deficiency.
The presence of P+PBac{XP5.WH5}BSC823 was verified using the PCR methods and primers described in FBrf0175003.
Exelixis, Inc. determined the insertion site of the progenitor P{XP}CanBd09902 to be Release 3 genomic coordinate 5073385 on the X chromosome. This corresponds to 4F5 on the Release 3 and Release 5 genome maps. The insertion site of the progenitor PBac{WH}f02325 is Release 5 genomic coordinate 5176617--5176617 on the X chromosome. This corresponds to 4F4 on the Release 5 genome map. Consequently, the cytological breakpoints of Df(1)BSC823 are predicted to be 4F4;4F5.